Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8191375 | 0.86 | KDM4E (0.35) | ALDH1A1KDM4EHTTTSHRHPGD | |
| SCHEMBL4574898 | 0.82 | KDM4E (0.33) | ALDH1A1KDM4EHTTHPGDHSD17B10 | |
| SCHEMBL6950787 | 0.81 | ALDH1A1 (0.42) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL7363046 | 0.80 | PDE4A (0.46) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL6837533 | 0.79 | PDE4A (0.49) | ALDH1A1KDM4EHPGDSMN1; SMN2ERN1 | |
| SCHEMBL5722750 | 0.79 | PDE4A (0.47) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL74659 | 0.79 | POLB (0.41) | POLB | |
| SCHEMBL7055204 | 0.78 | LMNA (0.48) | ALDH1A1KDM4EERN1LMNA | |
| SCHEMBL7052098 | 0.78 | PDE4A (0.50) | ALDH1A1KDM4ETSHRHPGDHSD17B10 | |
| SCHEMBL5722797 | 0.78 | ALDH1A1 (0.52) | ALDH1A1KDM4EHPGDHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008081282-A2 | PROCESS FOR THE SYNTHESIS OF N9-(3,5-DICHLORO-4-PYRIDYL)-6- DIFLUOROMETHOXYBENZO(4,5)FURO(3,2-C)PYRIDINE-9-CARBOXAMIDE AND SALTS THEREOF | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1831227-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | Glenmark Pharmaceuticals S.A. (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006064355-A2 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-0923568-B9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2003-08-13 | — | — | EP | disclosed |
| EP-0923568-B1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | ALTANA PHARMA AG (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6211203-B1 | RESPIRATORY SYSTEM DISORDERS, ANTIINFLAMMATORY AGENTS, ENZYME INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-04-03 | — | — | US | disclosed |
| EP-0923568-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998007715-A9 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEM FAB (DE) | 1999-04-29 | — | — | WO | disclosed |
| WO-1998007715-A1 | NOVEL BENZOFURAN-4-CARBOXAMIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | ALDH1A1 1591/4885KDM4E 2531/4885HTT 4643/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | ALDH1A1 1267/4885KDM4E 2674/4885HTT 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.